 |
|
pegylated liposomal doxorubicin hydrochloride
A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects; a liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | doxorubicin hydrochloride liposome
doxorubicin hydrochloride liposome injection
liposomal adriamycin
liposomal doxorubicin
liposomal doxorubicin hydrochloride
liposome-encapsulated doxorubicin
pegylated doxorubicin HCl liposome
Pegylated Liposomal Doxorubicin
S-Liposomal Doxorubicin
Stealth Liposomal Doxorubicin | | | | US brand names: | | DOXIL
Dox-SL
Evacet
LipoDox | | | | Foreign brand names: | | CAELYX
Doxilen | | | | Abbreviation: | | doxorubicin HCl liposome | | | | Code name: | | TLC D-99 | | | | Chemical structure name: | | (8S-cis)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride | | |
|
|
